サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1182201

強直性脊椎炎の世界市場規模調査＆予測：薬物クラス別（NSAIDs、TNF阻害剤、その他）、流通チャネル別（病院薬局、小売薬局、オンライン薬局）、地域分析、2022-2029年

Global Ankylosing Spondylitis Market Size study & Forecast, by Drug Class (NSAIDs, TNF Inhibitors and Others), and Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) and Regional Analysis, 2022-2029
出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
強直性脊椎炎の世界市場規模調査＆予測：薬物クラス別（NSAIDs、TNF阻害剤、その他）、流通チャネル別（病院薬局、小売薬局、オンライン薬局）、地域分析、2022-2029年
出版日: 2022年12月19日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

強直性脊椎炎の世界市場は、2021年に約53億8000万米ドルと評価され、予測期間2022-2029年には4.6%を超える健全な成長率で成長すると予測されています。

強直性脊椎炎は、脊椎の骨（椎骨）が癒合してしまう炎症性疾患を指します。この融合が背骨の柔軟性に影響し、姿勢が悪くなることがあります。肋骨が侵されると、深い呼吸が困難になることもあります。強直性脊椎炎の症状には、腰痛、臀部痛、肩こり、首の痛み、靭帯や腱の痛み、疲労感、寝汗などが含まれます。関節炎の有病率の増加、強直性脊椎炎の発生率の上昇、および主要な市場参加者の戦略的イニシアチブは、市場の成長を加速させる主要因となっています。

関節炎の有病率の上昇は、世界の強直性脊椎炎市場の成長に寄与しています。例えば、関節炎財団の推定によると-2019年現在、世界的に5400万人以上の大人と約30万人の子供が関節炎または別のタイプのリウマチ性疾患に罹患しています。さらに、強直性脊椎炎の発生率の増加も、本市場の成長を加速させています。例えば、米国脊椎炎協会によると、2020年現在、米国では170万人以上の成人がASに罹患しています。一方、約320万人が軸性脊椎関節炎を患っています。また、整形外科病院や診断センターの数が増加していることや、新興国での医療インフラの整備が進んでいることも、予測期間中の市場の有利な成長見通しを生み出すと考えられます。しかし、強直性脊椎炎に関連する高い治療費は、2022年から2029年の予測期間を通じて市場の成長を阻害します。

強直性脊椎炎の世界市場調査のために考慮された主要地域は、アジア太平洋、北米、欧州、中南米、および世界のその他の地域です。北米は、強直性脊椎炎の有病率の上昇や地域の医療インフラの成長などの要因により、市場シェアの面で主要な地域となっています。一方、アジア太平洋地域は、高齢者の増加やヘルスケアインフラの整備などの要因により、予測期間中に最も高いCAGRdで成長すると予想されています。

本調査の目的は、近年におけるさまざまなセグメントと国の市場規模を明らかにし、今後数年間の市場規模を予測することです。本レポートは、調査対象国における産業の質的および量的側面を取り込むように設計されています。

また、市場の将来的な成長を規定する促進要因や課題などの重要な側面に関する詳細な情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場の潜在的な機会も組み込んでいます。

薬物クラス別

非ステロイド性抗炎症薬

TNF阻害剤

その他

販売チャネル別

病院薬局

小売店

オンライン薬局

目次

第1章 エグゼクティブサマリー

  • 市場スナップショット
  • 世界・セグメント別市場の推定・予測、2019年～2029年
    • 強直性脊椎炎市場：地域別、2019年-2029年
    • 強直性脊椎炎市場（薬物クラス別）：2019-2029年
    • 強直性脊椎炎市場：流通チャネル別、2019年-2029年
  • 主な動向
  • 調査手法の紹介
  • 調査前提条件

第2章 強直性脊椎炎の世界市場定義と範囲

  • 調査の目的
  • 市場の定義と範囲
    • 調査対象範囲
    • 産業の進化
  • 調査対象年
  • 通貨換算レート

第3章 強直性脊椎炎の世界市場力学

  • 強直性脊椎炎市場のインパクト分析（2019-2029年）
    • 市場促進要因
      • 関節炎の有病率の増加。
      • 強直性脊椎炎の罹患率の増加
      • 主要な市場プレイヤーの戦略的な取り組み
    • 市場の課題
      • 強直性脊椎炎の高い治療費
    • 市場機会
      • 整形外科病院と診断センターの増加
      • 発展途上地域におけるヘルスケア・インフラの増加

第4章 強直性脊椎炎の世界市場産業分析

  • ポーターの5フォースモデル
    • 供給企業の交渉力
    • 買い手の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
  • ポーターの5フォースモデルへの未来的アプローチ（2019-2029年）
  • PEST分析
    • 政治的
    • 経済的
    • 社会的
    • 技術的
  • 投資採用モデル
  • アナリストの結論・提言
  • トップ投資機会
  • 主要成功戦略

第5章 リスク評価：COVID-19のインパクト

  • COVID-19が業界に与える全体的な影響の評価
  • COVID-19以前とCOVID-19以後の市場シナリオ

第6章 強直性脊椎炎の世界市場：薬物クラス別

  • 市場スナップショット
  • 強直性脊椎炎の世界市場：薬物クラス別、業績-ポテンシャル分析
  • 強直性脊椎炎の世界市場、薬物クラス別推定・予測2019～2029年
  • 強直性脊椎炎市場、サブセグメント分析
    • 非ステロイド性抗炎症薬
    • TNF阻害剤
    • その他

第7章：強直性脊椎炎の世界市場：流通チャネル別

  • 市場スナップショット
  • 強直性脊椎炎の世界市場：流通チャネル別、業績-ポテンシャル分析
  • 強直性脊椎炎の世界市場：流通チャネル別推定・予測（2019-2029年
  • 強直性脊椎炎市場、サブセグメント分析
    • 病院薬局
    • 小売薬局
    • オンライン薬局

第8章 強直性脊椎炎の世界市場：地域別分析

  • 強直性脊椎炎市場：地域別市場スナップショット
  • 北米
    • 米国
      • 薬剤クラス別の推定・予測、2019年～2029年
      • 流通チャネル別の推定・予測、2019年～2029年
    • カナダ
  • 欧州強直性脊椎炎市場スナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他の欧州地域
  • アジア太平洋地域の強直性脊椎炎市場スナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカの強直性脊椎炎市場スナップショット
    • ブラジル
    • メキシコ
  • 世界のその他の地域

第9章 競合情報

  • トップ市場戦略
  • 企業プロファイル
    • AbbVie Inc.
      • 主要情報
      • 概要
      • 財務情報（データの入手状況により異なります）
      • 製品概要
      • 最近の動向
    • Amgen, Inc,
    • Eli Lilly and Company
    • Gilead Sciences Inc
    • Janssen Pharmaceuticals
    • Merck & Co. Inc
    • Novartis AG,
    • Pfizer, Inc
    • Reliance Life Sciences Pvt. Ltd
    • UCB, Inc.,

第10章 調査プロセス

  • 調査プロセス
    • データマイニング
    • 分析
    • 市場推定
    • バリデーション
    • 出版
  • 調査属性
  • 調査の前提条件
図表

LIST OF TABLES

  • TABLE 1. Global Ankylosing Spondylitis Market, report scope
  • TABLE 2. Global Ankylosing Spondylitis Market estimates & forecasts by Region 2019-2029 (USD Billion)
  • TABLE 3. Global Ankylosing Spondylitis Market estimates & forecasts by Drug Class 2019-2029 (USD Billion)
  • TABLE 4. Global Ankylosing Spondylitis Market estimates & forecasts by Distribution Channel 2019-2029 (USD Billion)
  • TABLE 5. Global Ankylosing Spondylitis Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 6. Global Ankylosing Spondylitis Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 7. Global Ankylosing Spondylitis Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 8. Global Ankylosing Spondylitis Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 9. Global Ankylosing Spondylitis Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 10. Global Ankylosing Spondylitis Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 11. Global Ankylosing Spondylitis Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 12. Global Ankylosing Spondylitis Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 13. Global Ankylosing Spondylitis Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 14. Global Ankylosing Spondylitis Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 15. U.S. Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 16. U.S. Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 17. U.S. Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 18. Canada Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 19. Canada Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 20. Canada Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 21. UK Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 22. UK Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 23. UK Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 24. Germany Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 25. Germany Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 26. Germany Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 27. France Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 28. France Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 29. France Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 30. Italy Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 31. Italy Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 32. Italy Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 33. Spain Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 34. Spain Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 35. Spain Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 36. RoE Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 37. RoE Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 38. RoE Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 39. China Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 40. China Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 41. China Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 42. India Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 43. India Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 44. India Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 45. Japan Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 46. Japan Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 47. Japan Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 48. South Korea Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 49. South Korea Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 50. South Korea Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 51. Australia Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 52. Australia Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 53. Australia Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 54. RoAPAC Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 55. RoAPAC Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 56. RoAPAC Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 57. Brazil Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 58. Brazil Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 59. Brazil Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 60. Mexico Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 61. Mexico Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 62. Mexico Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 63. RoLA Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 64. RoLA Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 65. RoLA Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 66. Row Ankylosing Spondylitis Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 67. Row Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 68. Row Ankylosing Spondylitis Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 69. List of secondary sources, used in the study of global Ankylosing Spondylitis Market
  • TABLE 70. List of primary sources, used in the study of global Ankylosing Spondylitis Market
  • TABLE 71. Years considered for the study
  • TABLE 72. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Ankylosing Spondylitis Market, research methodology
  • FIG 2. Global Ankylosing Spondylitis Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Ankylosing Spondylitis Market, key trends 2021
  • FIG 5. Global Ankylosing Spondylitis Market, growth prospects 2022-2029
  • FIG 6. Global Ankylosing Spondylitis Market, porters 5 force model
  • FIG 7. Global Ankylosing Spondylitis Market, pest analysis
  • FIG 8. Global Ankylosing Spondylitis Market, value chain analysis
  • FIG 9. Global Ankylosing Spondylitis Market by segment, 2019 & 2029 (USD Billion)
  • FIG 10. Global Ankylosing Spondylitis Market by segment, 2019 & 2029 (USD Billion)
  • FIG 11. Global Ankylosing Spondylitis Market by segment, 2019 & 2029 (USD Billion)
  • FIG 12. Global Ankylosing Spondylitis Market by segment, 2019 & 2029 (USD Billion)
  • FIG 13. Global Ankylosing Spondylitis Market by segment, 2019 & 2029 (USD Billion)
  • FIG 14. Global Ankylosing Spondylitis Market, regional snapshot 2019 & 2029
  • FIG 15. North America Ankylosing Spondylitis Market 2019 & 2029 (USD Billion)
  • FIG 16. Europe Ankylosing Spondylitis Market 2019 & 2029 (USD Billion)
  • FIG 17. Asia pacific Ankylosing Spondylitis Market 2019 & 2029 (USD Billion)
  • FIG 18. Latin America Ankylosing Spondylitis Market 2019 & 2029 (USD Billion)
  • FIG 19. Global Ankylosing Spondylitis Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

目次

Global Ankylosing Spondylitis Market is valued at approximately USD 5.38 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 4.6% over the forecast period 2022-2029. Ankylosing Spondylitis refers to an inflammatory disease that causes the bones in the spine (vertebrae) to fuse. This fusing affects the spine's flexibility and can result in poor posture. If ribs are affected, it can be difficult to breathe deeply. Ankylosing Spondylitis symptoms include pain in the lower back, hips, and buttocks, stiffness in the lower back, hips, and buttocks. neck pain, ligament and tendon pain, tiredness, and night sweats among others. The growing prevalence of Arthritis and rising incidences of Ankylosing Spondylitis as well as strategic initiatives from leading market players are key factors accelerating the market growth.

The rising prevalence of Arthritis is contributing to the growth of the Global Ankylosing Spondylitis Market. For instance, according to Arthritis Foundation estimates - as of 2019, globally more than 54 million adults and approximately 300,000 children are affected by arthritis or another type of rheumatic disease. Moreover, increasing incidences of Ankylosing Spondylitis are also fueling up the growth of the Market. For instance, as per Spondylitis Association of America - as of 2020 more than 1.7 million adults in the U.S. are affected by AS. Whereas, around 3.2 million have a form of axial spondyloarthritis. Also, the rising number of orthopedic hospitals and diagnostic centers and growing healthcare infrastructure in developing regions would create lucrative growth prospects for the market over the forecast period. However, the high treatment cost associated with Ankylosing Spondylitis stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Ankylosing Spondylitis Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading region in terms of market share due to factors such as the rising prevalence of Ankylosing Spondylitis as well as growing healthcare infrastructure in the region. Whereas the Asia Pacific is expected to grow with the highest CAGRduring the forecast period, owing to factors such as rising geriatric individuals as well as growing healthcare infrastructure in the region.

Major market players included in this report are:

AbbVie Inc.

Amgen, Inc,

Eli Lilly and Company

Gilead Sciences Inc.

Janssen Pharmaceuticals

Merck & Co. Inc

Novartis AG,

Pfizer, Inc

Reliance Life Sciences Pvt. Ltd

UCB, Inc.,

Recent Developments in the Market:

  • In December 2021, US-based Pfizer has received FDA approval for its Tofacitinib. Tofacitinib is the first Janus kinase (JAK) inhibitor, or JAKi, that received approval for treatment of adults with active AS.

Global Ankylosing Spondylitis Market Report Scope:

Historical Data: 2019-2020-2021

Base Year for Estimation: 2021

Forecast period: 2022-2029

Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends

Segments Covered: Drug Class, Distribution Channel, Region

Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World

Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug Class

NSAIDs

TNF Inhibitors

Others

By Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Ankylosing Spondylitis Market, by Region, 2019-2029 (USD Billion)
    • 1.2.2. Ankylosing Spondylitis Market, by Drug Class, 2019-2029 (USD Billion)
    • 1.2.3. Ankylosing Spondylitis Market, by Distribution Channel, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Ankylosing Spondylitis Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Ankylosing Spondylitis Market Dynamics

  • 3.1. Ankylosing Spondylitis Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Growing prevalence of Arthritis.
      • 3.1.1.2. Growing incidences of Ankylosing Spondylitis
      • 3.1.1.3. Strategic initiatives from leading market players
    • 3.1.2. Market Challenges
      • 3.1.2.1. High treatment cost of Ankylosing Spondylitis
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Growing number of orthopedic hospitals and diagnostic centers
      • 3.1.3.2. Rising healthcare infrastructure in developing regions.

Chapter 4. Global Ankylosing Spondylitis Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Investment Adoption Model
  • 4.5. Analyst Recommendation & Conclusion
  • 4.6. Top investment opportunity
  • 4.7. Top winning strategies

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Ankylosing Spondylitis Market, by Drug Class

  • 6.1. Market Snapshot
  • 6.2. Global Ankylosing Spondylitis Market by Drug Class, Performance - Potential Analysis
  • 6.3. Global Ankylosing Spondylitis Market Estimates & Forecasts by Drug Class 2019-2029 (USD Billion)
  • 6.4. Ankylosing Spondylitis Market, Sub Segment Analysis
    • 6.4.1. NSAIDs
    • 6.4.2. TNF inhibitors
    • 6.4.3. Others

Chapter 7. Global Ankylosing Spondylitis Market, by Distribution Channel

  • 7.1. Market Snapshot
  • 7.2. Global Ankylosing Spondylitis Market by Distribution Channel, Performance - Potential Analysis
  • 7.3. Global Ankylosing Spondylitis Market Estimates & Forecasts by Distribution Channel 2019-2029 (USD Billion)
  • 7.4. Ankylosing Spondylitis Market, Sub Segment Analysis
    • 7.4.1. Hospital pharmacy
    • 7.4.2. Retail pharmacy
    • 7.4.3. Online pharmacy

Chapter 8. Global Ankylosing Spondylitis Market, Regional Analysis

  • 8.1. Ankylosing Spondylitis Market, Regional Market Snapshot
  • 8.2. North America Ankylosing Spondylitis Market
    • 8.2.1. U.S. Ankylosing Spondylitis Market
      • 8.2.1.1. Drug Class breakdown estimates & forecasts, 2019-2029
      • 8.2.1.2. Distribution Channel breakdown estimates & forecasts, 2019-2029
    • 8.2.2. Canada Ankylosing Spondylitis Market
  • 8.3. Europe Ankylosing Spondylitis Market Snapshot
    • 8.3.1. U.K. Ankylosing Spondylitis Market
    • 8.3.2. Germany Ankylosing Spondylitis Market
    • 8.3.3. France Ankylosing Spondylitis Market
    • 8.3.4. Spain Ankylosing Spondylitis Market
    • 8.3.5. Italy Ankylosing Spondylitis Market
    • 8.3.6. Rest of Europe Ankylosing Spondylitis Market
  • 8.4. Asia-Pacific Ankylosing Spondylitis Market Snapshot
    • 8.4.1. China Ankylosing Spondylitis Market
    • 8.4.2. India Ankylosing Spondylitis Market
    • 8.4.3. Japan Ankylosing Spondylitis Market
    • 8.4.4. Australia Ankylosing Spondylitis Market
    • 8.4.5. South Korea Ankylosing Spondylitis Market
    • 8.4.6. Rest of Asia Pacific Ankylosing Spondylitis Market
  • 8.5. Latin America Ankylosing Spondylitis Market Snapshot
    • 8.5.1. Brazil Ankylosing Spondylitis Market
    • 8.5.2. Mexico Ankylosing Spondylitis Market
  • 8.6. Rest of The World Ankylosing Spondylitis Market

Chapter 9. Competitive Intelligence

  • 9.1. Top Market Strategies
  • 9.2. Company Profiles
    • 9.2.1. AbbVie Inc.
      • 9.2.1.1. Key Information
      • 9.2.1.2. Overview
      • 9.2.1.3. Financial (Subject to Data Availability)
      • 9.2.1.4. Product Summary
      • 9.2.1.5. Recent Developments
    • 9.2.2. Amgen, Inc,
    • 9.2.3. Eli Lilly and Company
    • 9.2.4. Gilead Sciences Inc
    • 9.2.5. Janssen Pharmaceuticals
    • 9.2.6. Merck & Co. Inc
    • 9.2.7. Novartis AG,
    • 9.2.8. Pfizer, Inc
    • 9.2.9. Reliance Life Sciences Pvt. Ltd
    • 9.2.10. UCB, Inc.,

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption